Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.

World journal of gastroenterology - 21 Nov 2015

Fujita Ken-ichi, Kubota Yutaro, Ishida Hiroo, Sasaki Yasutsuna

Abstract excerpt

Irinotecan hydrochloride is a camptothecin derivative that exerts antitumor activity against a variety of tumors. SN-38 produced in the body by carboxylesterase is the active metabolite of irinotecan. After irinotecan was introduced for the treatment of metastatic colorectal cancer (CRC) at the end of the last century, survival has improved dramatically. Irinotecan is now combined with 5-fluorouracil, oxaliplatin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Antineoplastic Agents, Phytogenic
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biotransformation

Share to Colorectal Neoplasms

Share to Drug Dosage Calculations

Share to Irinotecan

Share to Neoplasm Metastasis

Source

Open in PubMed Open full text

Identifiers

PMID: 26604633
DOI: 10.3748/wjg.v21.i43.12234
PMCID: PMC4649109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.PMID 26604633Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Semantic proximity Read ↗

Insights, challenges, and future directions in irinogenetics.Semantic proximity Read ↗

Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.Semantic proximity Read ↗

UGT1A1 genotype-guided irinotecan dosing during neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A prospective analysis of SN-38 concentration.Semantic proximity Read ↗

Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.Semantic proximity Read ↗

UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?Semantic proximity Read ↗

Pharmacogenetics of irinotecan metabolism and transport: an update.Semantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.Semantic proximity Read ↗

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.Semantic proximity Read ↗

Pharmacogenetics of IrinotecanSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.